<p><strong>Cardiac conditions</strong>: Paroxetine does not produce clinically significant changes in blood pressure, heart rate and ECG. Nevertheless, as with all psychoactive drugs, caution is advised when treating patients with cardiac conditions.<br />
<br />
<strong>Epilepsy</strong>: As with other antidepressants, Paroxetine should be used with caution in-patients with epilepsy.<br />
<br />
<strong>Seizures</strong>: Overall, the incidence of seizures is &lt; 0.1% in patients treated with Paroxetine. Paroxetine should be discontinued in any patient who develops seizures.<br />
<br />
<strong>ECT</strong>: There is little clinical experience of concurrent administration of Paroxetine with ECT.<br />
<br />
<strong>Ability to drive/use machines</strong>: Clinical experience has shown that therapy with Paroxetine is not associated with impairment of cognitive or psychomotor function. However, as with all psychoactive drugs, patients should be cautioned about their ability to drive a car and operate machinery.<br />
<br />
<strong>Discontinuation of Treatment with Paroxetine</strong>: Recent clinical trials&nbsp;supporting the various approved indications of Paroxetine employed a taper phase regimen, rather than an abrupt discontinuation of treatment. The taper phase regimen used in GAD and PTSD clinical trials involved an incremental decrease in the daily dose by 10 mg/day at weekly intervals. When a daily dose of 20 mg/day was reached, patients were continued on this dose for 1 week before treatment was stopped.</p>